Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
All news
Biotechnology
A new report from industry analyst GlobalData finds that the compound annual growth rate (CAGR) of capital expenditure in public pharma companies increased by 4.7% between 2014 and 2018. 22 January 2020
Biotechnology
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs, which will serve to drive the market. 22 January 2020
Biotechnology
British biotech PhoreMost has entered into a multi-project collaboration with Tokyo-based Otsuka Pharmaceutical. 22 January 2020
Biotechnology
On Tuesday, the US Food and Drug Administration approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease (TED), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). 22 January 2020
Biotechnology
Asian-Pacific contract research organization (CRO) Novotech has issued a report describing a record year for clinical trials, as defined by numbers of studies, investigators, and patient enrollment. 22 January 2020
Biotechnology
A report from the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveals robust levels of investment in the UK biotech sector, indicating that companies raised £1.3 billion ($1.7 billion) in 2019. 22 January 2020
Biotechnology
The US Food and Drug Administration has granted Priority Review status to a submission from British drugmaker GlaxoSmithKlinefor belantamab mafodotin. 21 January 2020
Biotechnology
US biopharma firm Denovo Biopharma has entered into an exclusive option-to-license agreement with Rumpus Therapeutics for selected indications for DB102 (enzastaurin). 21 January 2020
Biotechnology
The pivotal Phase III trial evaluating Sino-America biotech firm BeiGene’s anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC), met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis, as assessed by independent review committee (IRC), the company announced today. 21 January 2020
Biotechnology
Danish cancer specialist Genmab has been awarded marketing authorization in the EU for a combination therapy of Darzalex (daratumumab) plus bortezomib, thalidomide and dexamethasone. 21 January 2020
Biotechnology
A new survey finds that nearly three quarters of global industry stakeholders identified immuno-oncology (I-O) or personalized medicine as the most impactful trends that will shape the pharmaceutical sector in 2020. 21 January 2020
Biotechnology
Swiss pharma giant Roche today announced that the European Commission has granted conditional marketing authorization for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab) (BR). 21 January 2020
Biotechnology
A new report into the bioengineered protein drugs market from industry analyst Fact.MR suggests that the sector could grow at a compound annual growth rate (CAGR) of 8.4% over the period from 2020 to 2025. 21 January 2020
Biotechnology
The European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. 20 January 2020
Biotechnology
Independent Dutch drugmaker Norgine has named Michael Lange as general manager for Germany. 20 January 2020
Biotechnology
Chinese company Hutchison China MediTech, a firm commonly-known as Chi-Med, has shown the potential of its wholly-owned asset surufatinib in another indication. 20 January 2020
Biotechnology
A US Food and Drug Administration (FDA) advisory panel vote on whether to approve Durect Corporation’s painkiller Posimir (bupivacaine) ended in a tie. 20 January 2020
Biotechnology
According to the UK’s health technology assessor, German pharma major Bayer’s Vitrakvi (larotrectinib), a new treatment for a range of cancers, can’t be recommended for use in the National Health Service (NHS) because at its current price, it doesn’t have the potential to be cost-effective. 20 January 2020
Biotechnology
US CRISPR gene-editing firm Emendo Biotherapeutics has announced a Series B $61 million investment led by Japanese biotech AnGes, reflecting its strategic interest in partnering with Emendo and increasing its stake in the company to 32%. 18 January 2020
Biotechnology
US immuno-oncology company OncoSec Medical Incorporated has snubbed an attempted takeover by Korea’s Alpha Holdings. 17 January 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze